Treatment for hepatitis C is associated with a reduction in cardiovascular events.
All articles by Roxanne Nelson, BSN, RN
CAP guidelines recommend transitioning to an oral beta-lactam or fluoroquinolone regimen when patients are clinically stable, but because of common adverse effects, stewardship efforts are frequently focused on reducing initial fluoroquinolone use for CAP therapy.
Latest News Your top articles for ThursdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses